BRIEF

on CROSSJECT (EPA:ALCJ)

Crossject: Publication of Clinical Data on ZEPIZURE®

Stock price chart of CROSSJECT (EPA:ALCJ) showing fluctuations.

Pharmaceutical company Crossject announces the publication of clinical data on its product ZEPIZURE® in the peer-reviewed journal Neurology and Therapy. This research, carried out in 2022, highlights the bioequivalence of ZEPIZURE® compared to Dormicum®, a drug used in Europe.

ZEPIZURE® uses the ZENEO® needle-free auto-injector to administer midazolam. The study shows low variability compared to intranasal administration methods, which represents a significant advantage. Rapid absorption of the drug would allow increased effectiveness from the first minutes following injection.

The study, carried out on 40 healthy subjects, evaluated the relative bioavailability of midazolam. The results confirm that ZEPIZURE® offers safe, effective and rapid administration, comparable in terms of safety and variability to traditional intramuscular injection.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all CROSSJECT news